Eden Research Share Discussion Threads

[littlealbatross2] 22/3/2018 16:39

Sean Smith did seem quite confident (and rather articulate.)

[northwick] 22/3/2018 16:28

Pleased to see that YouTube video has been viewed 208 times so far. more than 240% increase from early this morning. pity the share price is not moving correspondingly.

[weyweyumfozo] 22/3/2018 15:29

Yes,

I've just watched it again. He said that Eden should have approval for use of 3OLGY for next year's US growing season. That makes it available to an additional 9% of world wine production volume (bringing the total to about 62%).

[bjlk] 22/3/2018 14:57

That you tube link to the interview is well worth a watch... I thought Sean came across well...

[supersonico] 22/3/2018 10:51

Parking;




jean pierre lachambre

Career development in the agro-supply sector (phyto pharmacy, seeds). Until 1999 at PIONEER (subsidiary of Dupont de nemours) world leader in plant genetics and major player in the development and integration of new technologies.
Then at Dispagri and In Terra Pro, subsidiaries of InVivo (6 Billion €) until January 2016.
On February 1, 2016 I joined Sumi Agro, a subsidiary of Sumitomo Corporation Group.

I am an engineer, manager of men and projects and am passionate about strategic thinking and its operational implementation.




Specialties: Management, Business Development, Marketing
..............

Sales manager
Company Name
DISPAGRI SAS
Employed Dates
Aug 2000 - Present
Employment Duration
17 yrs 8 mos
Dispagri is a service provider in the agricultural trades and green leisure (gardens and green spaces)

Marketed plant and seed protection products from leading market-leading suppliers.
Services provided:
- Marketing
- commercial, ADV and promotion
- training
- logistics (seveso 2 and iso 14001)

Activity area: Rhône Alpes, Auvergne, Limousin, Burgundy, Center / Berry, South East.

[supersonico] 22/3/2018 09:49

The Sipcam comments;

Sean Smith talking about the Micro Particle high potency encapsulation being used in very large market. Sipcam taking conventional chemistry of roughly 20 active ingredients and package them up in Eden Tech.

"We've demonstrated the ability of our encapsulation technology to improve these (conventional)products in a variety of different ways and so this is a high priority for Sipcam"

[northwick] 22/3/2018 08:01

That YouTube video has been viewed 65 times in total so far. Looks like potential investors out there haven't heard about Eden.A lot more work to be done by Eden,

[northwick] 21/3/2018 16:23

Hear Shore Capital have come out with a new research note.

[supersonico] 21/3/2018 07:33

In this episode Sanjiv Rana, Editor of Agrow, speaks to Jonathan Shoham, consulting analyst for Phillips McDougall to analyse the outcome of the previous year for the crop protection market, and to explore the factors contributing to global market development.

Interesting Podcast with Bio-contol mentioned from 16min..
Points of interest for me.. Biocontrol / Endocrine disruptors/ Regulation EU & Brazil/ Patents /Cotton / soya


........................................................................................................


Bio control --Brazil//



Sipcam in Brazil

[supersonico] 20/3/2018 21:41

quazie12 - 17 Dec 2017 - 20:49:13 - 3030 of 3562
Eden Research - EDEN

I don’t subscribe to Jacknife’s way of thinking.
..........................................................

Not many do Q12

[supersonico] 20/3/2018 20:16

I knew it might touch a nerve Fraudyboy.

Chin Chin

[supersonico] 20/3/2018 18:34

Eden Research sales jump as wine producers warm to natural pesticide

Natural pesticides group Eden Research PLC (LON:EDEN) posted a sharply reduced loss in 2017 as sales jumped more than four-fold.
Eden uses terpenes produced by plants as the basis of its products and received EU approval in France for its fungicidal product Mevalone (3AEY) during the year.
READ: Eden Research shares surge as it celebrates French marketing approval for wine fungus treatment
Revenues for the year to December rose to £1.9mln (£0.4mln) while losses fell to £763,000 (£1.91mln) as first French sales came through.
It means Mevalone is now available as a treatment for grape botrytis in the top three wine producing countries in the world, (France, Italy, Spain).
EU approval has also now been granted in Cyprus, Albania and Portugal, which means most countries in southern Europe have approved the product.
Over the year, collaborations were signed with Sipcam for its encapsulation technology and Eastman Chemical for a new treatment (Cedroz) for nematodes, a soil-dwelling parasite.
Eden expects to launch Cedroz towards the end of 2019, “which should have an immediate, positive impact on revenue with a market opportunity which is potentially far greater even than that of Mevalone”.

Lykele van der Broek, chairman, said: "The strong growth achieved in 2017, driven by new regulatory approvals, is expected to continue in the current year and consequently the board remains confident that 2018 will be another year of strategic and financial progress."
Cash at the year-end was £3.7mln.

[supersonico] 20/3/2018 18:12

Fraudyboy..care to share the details of the little chat the Chapel down boys had with you about Mevalone..LOL

or would you rather keep that quiet??

They did rather rain on your parade..

[supersonico] 20/3/2018 15:40

Oh Good Fraudyboy, thanks.. that's an improvement on your last prediction of 0p by end of 2017 and your comedy 'How wrong could I get it'.. stock market crash..LOL

Such insight..your truly gifted..

Were lucky to have you around for help with the numbers.

[investingisatrickygame] 20/3/2018 15:39

JakNife

In terms of quantity of products sold last year was the first year, as you know. Sales were only for Mevalone and ARAW (same thing).

When you talk about next year (2018) you must allow for increased territories and penetration of existing territories for Mevalone as well as associated licence extensions

Bayer - Likely

"Eden's partner for animal health applications in North America, Bayer Animal Health ("Bayer"), continues to make steady progress with the four products that it is intending to commercialise: a shampoo, a conditioner, a spray and an otic flush. These products are regarded by Bayer as an important element of their strategy to diversify their product offering and incorporate new, sustainable actives. A significant amount of work, including in vitro and in vivo studies, has been undertaken. It is expected that sales will commence in 2018. Eden remains confident that the products, once commercialised, will command a strong market share in the large North American market for companion animal health products"

Terpene Tech - Possible

"Further applications of Eden's technology remain in the development stage. However, TerpeneTech reports good progress with the development of its underarm deodorant product. This product will be marketed as a natural human deodorant product with superior, long-lasting performance derived, in part, from the use of Eden's microencapsulation system. There are currently advanced-stage discussions with potential commercial partners, and, assuming success with these, TerpeneTech anticipates product launches toward the end of 2018."

AND as and when institutions and analysts take Eden seriously, if they do, they will also be looking to Cedroz sales in 2019 and beyond.

This is without the commercial development and sales of anything else in this timeframe.

[supersonico] 20/3/2018 14:49

Eden Research narrows losses on massive revenue gains

[bjlk] 20/3/2018 10:13

I want to reiterate that I'm still excited by the tech/product......

[bjlk] 20/3/2018 10:11

What a brilliant summary investingisatrickygame, maybe powerscourt and Eden are listening??Want to take over as head of strategy??

[weyweyumfozo] 20/3/2018 09:42

A few snippets from the Results:

"Towards the end of 2019, we expect to see the launch of Cedroz which should have an immediate, positive impact on revenue with a market opportunity which is potentially far greater even than that of Mevalone."

Head lice treatment product - "The process for regulatory clearances in both the US and the EU should now complete within the first half of 2018 enabling product sales in both regions during the second half of 2018."

Underarm deodorant product - "TerpeneTech anticipates product launches toward the end of 2018."

"Eden's partner for animal health applications in North America, Bayer Animal Health ("Bayer"), continues to make steady progress with the four products that it is intending to commercialise: a shampoo, a conditioner, a spray and an otic flush. ........................ It is expected that sales will commence in 2018. Eden remains confident that the products, once commercialised, will command a strong market share in the large North American market for companion animal health products."